Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Causes & Control
Erschienen in: Cancer Causes & Control 8/2012

01.08.2012 | Review article

Depression as a risk factor for breast cancer: investigating methodological limitations in the literature

verfasst von: Patrick Pössel, Erica Adams, Jeffrey C. Valentine

Erschienen in: Cancer Causes & Control | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A relationship between depression and the development of breast cancer has not been convincingly shown in the research conducted over the past three decades.

Methods

In an effort to better understand the conflicting results, a review was conducted focusing on the methodological problems associated with this literature, including time frame between the assessment of depression and the diagnosis of breast cancer and the use of somatic items in measuring depression. Fifteen breast cancer prospective studies were reviewed.

Results

While twelve of the studies found positive associations between depression and breast cancer development, three studies found negative associations. With regard to the predictive associations between depression and breast cancer incidence, the findings revealed that (a) studies using a longer time frame found a stronger association than studies using a shorter time frame and (b) studies utilizing depression measures that did not contain somatic items found a smaller association than studies utilizing depression measures that did contain these items.

Conclusions

Future studies should ensure that sufficient periods of time between the measurement of depression and the assessment of cancer and avoid measuring depression using somatic items.
Fußnoten
1
It should be noted that Gross et al.’s [49] publication is an update of Gallo et al. [47] including an additional wave of data collection, which extends the time frame from 13 to 24 years. In addition, both studies use only partially identical methodological control variables.
 
Literatur
1.
2.
3.
Snow HL (1893) Cancer and the cancer process. Churchill, London
4.
Ader R, Cohen N, Felten D (1995) Psychoneuroimmunology: interaction between the nervous system and the immune system. Lancet 345:99–103PubMedCrossRef
5.
Andersen BL, Farrar WB, Golden-Kreutz D et al (1998) Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 90:30–36PubMedCrossRef
6.
Schleifer SJ, Keller SE, Bartlett JA, Eckholdt HM, Delaney BR (1996) Immunity in young adults with major depressive disorder. Am J Psychiatry 153:477–482PubMed
7.
Kiecolt-Glaser JK, Robles TF, Heffner KL, Loving TJ, Glaser R (2002) Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol 13:165–169PubMedCrossRef
8.
Glaser R, Thorn BE, Tarr KL, Kiecolt-Glaser JK, D’Ambrosio SM (1985) Effects of stress on methyltransfease synthesis: an important DNA repair enzyme. Br J Health Psychol 4:403–412CrossRef
9.
Pulaski L, Kania K, Ratajewski M et al (2005) Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol 2005(96):229–234CrossRef
10.
Su F, Ouyang N, Zhu P et al (2005) Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochem Biophys Res Commun 329:888–897PubMedCrossRef
11.
Ticher A, Haus E, Ron IG et al (1996) The pattern of hormonal circadian time structure (acrophase) as an assessor of breast cancer risk. Int J Cancer 65:591–593PubMedCrossRef
12.
Butow PN, Hiller JE, Price MA, Thackway SV, Kricker A, Tennant CC (2000) Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer. J Psychosom Res 49:169–181PubMedCrossRef
13.
Dalton SO, Boesen EH, Ross L, Schapiro IR, Johansen C (2002) Mind and cancer: do psychological factors cause cancer? Eur J Cancer 38:1313–1323PubMedCrossRef
14.
Garssen B (2004) Psychological factors and cancer development: evidence after 30 years of research. Clin Psychol Rev 24:315–338PubMedCrossRef
15.
McGee R, Williams S, Elwood M (1994) Depression and the development of cancer: a meta-analysis. Soc Sci Med 38:187–192PubMedCrossRef
16.
McKenna MC, Zevon MA, Corn B, Rounds J (1999) Psychosocial factors and the development of breast cancer: a meta-analysis. Health Psychol 18:520–531PubMedCrossRef
17.
Oerleman MEJ, van den Akker M, Schuurman AG, Kellen E, Buntinx F (2007) A meta-analysis on depression and subsequent cancer risk. Clin Pract Epidemiol Mental Health 3:29CrossRef
18.
Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54:269–282PubMedCrossRef
19.
Friberg S, Mattson S (1997) On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65:284–297PubMedCrossRef
20.
Spratt JS, Meyer JS, Spratt JA (1996) Rates of growth of human solid neoplasms: part II. J Surg Oncol 61:68–83PubMedCrossRef
21.
Eskelinen M, Ollonen P (2011) Beck Depression Inventory in patients with breast disease and breast cancer: a prospective case–control study. In Vivo 25:111–116PubMed
22.
Eskelinen M, Ollonen P (2011) Montgomery-Asberg Depression Rating Scale (MADRS) in healthy study subjects, in patients with breast disease and breast cancer: a prospective case–control study. Anticancer Res 31:1065–1069PubMed
23.
Eskelinen M, Ollonen P (2011) Montgomery-Asberg Depression Rating Scale (MADRS) in healthy study subjects, in patients with breast disease and breast cancer: a prospective case–control study. Anticancer Res 31:1065–1069PubMed
24.
Eskelinen M, Ollonen P (2011) Measurement of pessimism: Hopelessness Scale in healthy study subjects, in patients with breast disease and breast cancer: a prospective case–control study in Finland. Anticancer Res 31:4019–4023PubMed
25.
Ollonen P, Lehtonen J, Eskelinen M (2005) Anxiety, depression and the history of psychiatric symptoms in patients with breast disease: a prospective case–control study in Kuopio, Finland. Anticancer Res 25:2527–2534PubMed
26.
Dugan W, McDonald MV, Passik SD, Rosenfeld BD, Theobald D, Edgerton S (1998) Use of the Zung Self-Rating Depression Scale in cancer patients: feasibility as a screening tool. Psycho-Oncology 7:483–493PubMedCrossRef
27.
Wedding U, Koch A, Röhrig B et al (2007) Requestioning depression in patients with cancer: contribution of somatic and affective symptoms to Beck’s Depression Inventory. Ann Oncol 18:1875–1881PubMedCrossRef
28.
Endicott J (1984) Measurement of depression in patients with cancer. Cancer 53:2243–2248PubMed
29.
Cavaugh S (1984) Diagnosing depression in the hospitalised patient with chronic medical illness. J Clin Psychiatry 45:13–16
30.
Ryder AG, Yang J, Zhu X, Yao S, Yi J, Heine SJ, Bagby RM (2008) The cultural shaping of depression: somatic symptoms in China, psychological symptoms in North America? J Abnorm Psychol 117:300–313PubMedCrossRef
31.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. American Psychiatric Association, Washington, DC
32.
Akechi T, Nakano T, Akizuki N et al (2003) Somatic symptoms for diagnosing major depression in cancer patients. Psychosomatics 44:244–248PubMedCrossRef
33.
Bleiker EM, Hendriks JH, Otten JD, Verbeek AL, van der Ploeg HM (2008) Personality factors and breast cancer risk: a 13-year follow-up. J Natl Cancer Inst 100:213–218PubMedCrossRef
34.
Bushman BJ, Wang MC (2009) Vote-counting procedures in meta-analysis. In: Cooper H, Hedges LV, Valentine JC (eds) The handbook of research synthesis and meta-analysis, 2nd edn. Russell Sage Foundation, New York, pp 207–220
35.
Aro AR, de Koning HJ, Schreck M, Hendriksson M, Anttila A, Pukkala E (2005) Psychological risk factors of incidence of breast cancer: a prospective cohort study in Finland. Psychol Med 35:1515–1521PubMedCrossRef
36.
Bleiker EMA, van der Ploeg JHCL, Hendriks HJA (1996) Personality factors and breast cancer development: a prospective longitudinal study. J Natl Cancer Inst 88:1478–1482PubMedCrossRef
37.
Penninx BW, Guralnik JM, Pahor M et al (1998) Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90:1888–1893PubMedCrossRef
38.
Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Flint J (2007) Cancer in people with depression and anxiety: record-linkage study. Soc Psychiatry Epidemiol 42:683–689CrossRef
39.
Nykliček I, Louwman WJ, Van Nierop PW, Wijnands CJ, Coebergh JW, Pop VJ (2003) Depression and the lower risk for breast cancer development in middle-aged women: a prospective study. Psychol Med 33:1111–1117PubMedCrossRef
40.
Gallo JJ, Armenian HK, Ford DE, Eaton WW, Khachaturian AS (2000) Major depression and cancer: the 13-year follow-up of the Baltimore epidemiologic catchment area sample (United States). Cancer Causes Control 11:751–758PubMedCrossRef
41.
Gross AL, Gallo JJ, Eaton WW (2010) Depression and cancer risk: 24 years of follow-up of the Baltimore epidemiologic catchment area sample. Cancer Causes Control 21:191–199PubMedCrossRef
42.
Jacobs JR, Bovasso GB (2000) Early and chronic stress and their relation to breast cancer. Psychol Med 30:669–678PubMedCrossRef
43.
Lichtman JH (1996) Are depressive symptoms, social networks and social support, or self-evaluated health measures predictive of cancer incidence and stage of diagnosis? Evidence from a prospective community based sample of elderly New Haven residents (Doctoral dissertation). Yale University, New Haven
44.
Hahn RC, Petitti DB (1988) Minnesota Multiphasic Personality Inventory-rated depression and the incidence of breast cancer. Cancer 61:845–848PubMedCrossRef
45.
Hjerl K, Andersen EW, Keiding N et al (1999) Breast cancer risk among women with psychiatric admission with affective or neurotic disorders: a nationwide cohort study in Denmark. Br J Cancer 81:907–911PubMedCrossRef
46.
Dalton SO, Mellemkjaer L, Olsen JH, Mortensen PB, Johansen C (2002) Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969–1993. Am J Epidemiol 155:1088–1095PubMedCrossRef
47.
Kaplan GA, Reynolds P (1988) Depression and cancer mortality and morbidity: prospective evidence from the Alameda County study. J Behav Med 11:1–13PubMedCrossRef
48.
Knekt P, Raitasalo R, Heliövaara M et al (1996) Elevated lung cancer risk among persons with depressed mood. Am J Epidemiol 144:1096–1103PubMedCrossRef
49.
Chen Y-H, Lin H-C (2011) Increased risk of cancer subsequent to severe depression-A nationwide population-based study. J Affect Disord 131:200–206PubMedCrossRef
50.
Liang J-A, Sun L-M, Muo C-H et al (2011) The analysis of depression and subsequent cancer risk in Taiwan. Cancer Epidemiol Biomark Prev 20:473–475CrossRef
51.
Schuurman AG, van den Akker M, Ensinck KTJL et al (2001) Does depression increase susceptibility for somatic disease? NWO-report. Research Institute Ex Tra, Maastricht
52.
Kuehner C, Holzhauer S, Huffziger S (2007) Decreased cortisol response to awakening is associated with cognitive vulnerability to depression in a nonclinical sample of young adults. Psychoneuroendocrinology 32:199–209PubMedCrossRef
53.
Nolen-Hoeksema S, Morrow J (1991) A prospective study of depression and posttraumatic stress symptoms after a natural disaster: the 1989 Loma Prieta earthquake. J Pers Soc Psychol 61:115–121PubMedCrossRef
Metadaten
Titel
Depression as a risk factor for breast cancer: investigating methodological limitations in the literature
verfasst von
Patrick Pössel
Erica Adams
Jeffrey C. Valentine
Publikationsdatum
01.08.2012
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 8/2012
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0014-y

Weitere Artikel der Ausgabe 8/2012

Cancer Causes & Control 8/2012 Zur Ausgabe

Original paper

Comparison of breast and cervical cancer screening utilization among rural and urban Hispanic and American Indian women in the Southwestern United States

Original paper

Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case–control study

Original paper

Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort

Original paper

Hematologic malignancies: an opportunity to fill a gap in cancer surveillance

Original paper

Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Review article

Height and pancreatic cancer risk: a systematic review and meta-analysis of cohort studies

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise